Compare DexCom, Inc. (DXCM) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Nutanix Inc — how do they compare? DexCom, Inc. trades at $77.96 (market cap $28.06B), while Nutanix Inc trades at $55.89 (market cap $14.76B). The key difference: DexCom, Inc. is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, Nutanix Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | NTNX | |
|---|---|---|
Market Cap | $28.06B | $14.76B |
Sector | Health | Technology |
52-Week High | $89.53 | $81.12 |
52-Week Low | $54.84 | $34.41 |
Enterprise Value | $27.03B | $14.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Nutanix (NTNX) trades at $56.09, up 1.12% with a bullish technical outlook and strong fundamental momentum. The stock exhibits robust earnings beats, with Q1 2026 EPS of $0.47 surpassing the $0.36 estimate, and revenue growth projected to $2.7B in 2026. Analyst sentiment is positive with a $57.80 consensus target, and recent news highlights AI infrastructure advancements, including NVIDIA certification for Nutanix Unified Storage.
The outlook for NTNX is favorable, driven by consistent earnings outperformance and strategic positioning in hybrid cloud computing. Key risks include high valuation multiples and competitive pressures. Investment opportunity lies in sustained execution and AI-driven growth, though investors should monitor margin sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
